Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Park, Jun Bean ^a   Kim, Baek Kyung ^a   Kwon, Yoo Wook ^a,b   Muller, Dominik N ^c   Lee, Hyun Chae ^a   Youn, Seock Won ^a   Choi, Young Eun ^a   Lee, Sae Won ^a,b   Yang, Han Mo ^a   Cho, Hyun Jai ^a,b   Park, Kyung Woo ^a   Kim, Hyo Soo ^a,b,d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAPAMYCIN; ROSIGLITAZONE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR AP 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY MUSCLE; ARTICLE; CAROTID ARTERY INJURY; CHROMATIN IMMUNOPRECIPITATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG ELUTING STENT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SMOOTH MUSCLE FIBER; THROMBOGENESIS; ANIMAL; BIOLOGICAL MODEL; CATHETERIZATION; DISEASE MODEL; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; MONOCYTE; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; UMBILICAL ARTERY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CATHETERIZATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIPOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; PACLITAXEL; PHOSPHORYLATION; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIROLIMUS; THIAZOLIDINEDIONES; THROMBOPLASTIN; UMBILICAL ARTERIES;

EID: 82255179593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028327     Document Type: Article

References (46)

1. Boyle JG, Logan PJ, Ewart MA, Reihill JA, Ritchie SA, et al. (2008) Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem 283: 11210-11217.
2. Liu HR, Tao L, Gao E, Qu Y, Lau WB, et al. (2009) Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation-a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res 81: 344-352.
3. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA, (2001) Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134: 61-71.
4. Abdelrahman M, Sivarajah A, Thiemermann C, (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781.
5. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
6. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, et al. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135.
7. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360: 2503-2515.
8. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108: 2941-2948.
9. Mackman N, (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24: 1015-1022.
10. Nemerson Y, (1988) Tissue factor and hemostasis. Blood 71: 1-8.
11. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC, (2005) Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 112: 341-349.
12. Steffel J, Luscher TF, Tanner FC, (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113: 722-731.
13. Stahli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, et al. (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99: 149-155.
14. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, et al. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112: 2002-2011.
15. Chen M, Ichiki T, Ohtsubo H, Imayama I, Inanaga K, et al. (2007) Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance. Hypertens Res 30: 971-978.
16. Loke YK, Kwok CS, Singh S, (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309.
17. Pucci A, Formato L, Muscio M, Brscic E, Pizzimenti S, et al. (2011) PPARgamma in coronary atherosclerosis: In vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis 218: 479-485.
18. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, et al. (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89: 2728-2735.
19. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, et al. (2005) Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25: 1903-1909.
20. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, et al. (1997) Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 100: 2276-2285.
21. Napoleone E, Di Santo A, Lorenzet R, (1997) Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 89: 541-549.
22. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, et al. (2002) Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 277: 25032-25039.
23. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, et al. (1995) Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem 270: 26419-26432.
24. Morrison A, Yan X, Tong C, Li J, (2011) Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol 301: H895-902.
25. Mackman N, (1995) Regulation of the tissue factor gene. FASEB J 9: 883-889.
26. Coyle AT, Kinsella BT, (2006) Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol 71: 1308-1323.
27. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, et al. (2001) Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104: 473-479.
28. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al. (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356: 1009-1019.
29. He M, He X, Xie Q, Chen F, He S, (2006) Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res 117: 579-590.
30. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, et al. (1999) Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 19: 531-537.
31. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, et al. (1997) Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 17: 2964-2974.
32. Caplice NM, Mueske CS, Kleppe LS, Peterson TE, Broze GJ Jr, et al. (1998) Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 83: 1264-1270.
33. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, et al. (1993) Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 91: 2253-2259.
34. Watt J, Wadsworth R, Kennedy S, Oldroyd KG, (2008) Pro-healing drug-eluting stents: a role for antioxidants? Clin Sci (Lond) 114: 265-273.
35. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, et al. (1995) Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95: 1869-1876.
36. Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, et al. (2009) New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 29: 472-479.
37. Li D, August S, Woulfe DS, (2008) GSK3beta is a negative regulator of platelet function and thrombosis. Blood 111: 3522-3530.
38. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L, (2004) Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 110: 452-459.
39. Yang L, An HX, Deng XL, Chen LL, Li ZY, (2003) Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway. Acta Pharmacol Sin 24: 429-434.
40. Paget MB, Murray HE, Bailey CJ, Flatt PR, Downing R, (2011) Rotational co-culture of clonal beta-cells with endothelial cells: effect of PPAR-gamma agonism in vitro on insulin and VEGF secretion. Diabetes Obes Metab 13: 662-668.
41. Lloyd S, Hayden MJ, Sakai Y, Fackett A, Silber PM, et al. (2002) Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem Biol Interact 142: 57-71.
42. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, et al. (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110: 301-308.
43. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, et al. (2000) Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 157: 111-122.
44. Park KW, Yang HM, Youn SW, Yang HJ, Chae IH, et al. (2003) Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 23: 1364-1369.
45. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP, (1999) Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 128: 1570-1576.
46. Thornton SR, Wang AF, Smith FL, (1997) Characterization of neonatal rat morphine tolerance and dependence. Eur J Pharmacol 340: 161-167.